Milestone's etripamil approved in China by NMPA; first approval outside US

Milestone Pharmaceuticals Inc.

NMPA approved etripamil nasal spray for PSVT in adults on Sept 3, 2026; first approval outside US.
Approval triggers $2.0M milestone payment to Milestone; Everest Medicines to commercialize in Greater China.
Milestone eligible for up to $98.0M in milestones and tiered royalties up to 18% on future sales.
Based on Phase 3 RAPID and JX02002; JX02002 showed HR=3.002 (95% CI 1.578-5.711, p=0.0005) for conversion to sinus rhythm.
No serious adverse events reported within 24 hours after dosing across Phase 3 studies.

Featured in Daily 8-K Digest

Selected #5 for 2026-09-03. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.